Is Viking Therapeutics Inc (VKTX) overvalued? · $3.97B cap
Viking Therapeutics Inc (VKTX) is a biotechnology company listed on US.
This page asks whether Viking Therapeutics Inc (VKTX) looks expensive on cached numbers — not a short thesis.
Latest reported VKTX revenue for 2025-12-31 was $0. Net income was -$359.6M. VKTX currently screens at market cap $3.97B.
VKTX currently screens at market cap $3.97B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VKTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VKTX stock page for the full model, not this heading.
Not investment advice.